November 18, 2026 | AI, Pharma, Product Launch, commercial, healthcare
Inizio helped Tonix successfully launch the first FDA-approved therapy in its class in almost two decades by delivering an integrated, AI-enabled commercialization program spanning analytics, field operations, and launch readiness.

Tonix was preparing to launch the first FDA-approved therapy in its class in almost two decades. Tonmya is indicated for fibromyalgia, so it falls primarily into neurology, though pain management is another indicator. Tonix needed to rapidly establish a nationwide commercial infrastructure in the US while retaining the flexibility to respond to changing market dynamics.
This required coordinated support spanning market analytics, field deployment, Medical Affairs, launch readiness, and payer value demonstration. In doing so, Tonix sought to avoid building a large permanent in-house commercial organization.
Through a single project management office, Inizio delivered an integrated commercialization program applying its 4D methodology (Diagnose, Design, Deploy, Drive). The solution delivered was a combined commercial strategy, analytics, and field deployment within a single integrated operating model.
The team used publicly available claims data – refined with data collected over the prior nine months – and delivered advanced market analytics to optimize territory design, field force sizing, and commercial planning before deploying a national sales organization.
Inizio expanded the commercial model to include MSLs and supported launch readiness through training, congress execution, and payer value demonstration. The team applied AI-enabled analytics to continuously refine HCP targeting, messaging, and field deployment based on customer behavior and sentiment – ensuring a continuously improving launch model rather than a static commercial plan.
Read the full case study here.
This content was provided by Inizio